Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Novel therapies for myelofibrosis

Jean-Jacques Kiladjian • 15 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Navitoclax Navtemadlin Pelabresib Ruxolitinib

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, highlights novel approaches investigated in the treatment of myelofibrosis at EHA 2020, these include KRT-232, an MDM2 inhibitor, as well as pelabresib (CPI-0610), a BET inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jean-Jacques Kiladjian

Preliminary results from trials targeting mutant CALR for the treatment of MPNs 1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs 0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care 1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025
MPN Sessions: Key updates from EHA 2022
Claire Harrison et al. • 12 Jun 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals